CSF-1 has been described as the most important tumor-derived factor leading to monocyte recruitment through CCL2/CCR2 interaction, so CCR2 blockade therapies have been effective in suppressing TAM recruitment [132]. This evidence concerns the gene CCL2 and neoplasm.